View New Articles By
Five researchers have been announced as the recipients of the Albany Medical Center Prize in Medicine and Biomedical Research for 2017. They have made important contributions to the development of CRISPR-Cas9, a gene engineering technology that harnesses a naturally occurring bacterial immune system process. The technology has revolutionized biomedical research and provided new hope for the treatment of genetic diseases and more.
They met on the dance floor at a party thrown by postdoctoral students from each of their labs at the University of Washington and Fred Hutchinson Cancer Research Center in Seattle, and reconnected a couple months later at a genetics lecture. "And then she finally gave me her phone number!" says Steve.
By Michael Caligiuri, MD, President of the American Association for Cancer Research
It’s been a long time since we’ve seen the kind of strong national commitment that exists today to support medical research.
Of course, this enthusiasm is more than justified because of the large number of unprecedented research opportunities that are at the ready to propel us toward defeating cancer and the numerous other diseases that afflict so many Americans.
The FDA approved Idhifa for acute myeloid leukemia (AML), the result of important contributions from Hai Yan, MD, PhD (Damon Runyon Scholar ‘05-‘07), of Duke University Medical Center, Durham, and Omar Abdel-Wahab, MD (Damon Runyon Clinical Investigator ‘13-‘16), of Memorial Sloan Kettering Cancer Center, New York. They made independent discoveries about mutations in the IDH2 gene and how these contribute to the development of AML.
By Nadia Halim, Damon Runyon Science Writer
After mounting excitement in the last five years over a revolutionary approach to cancer therapy, patients are one step closer to seeing CAR T immunotherapy approved by the FDA for acute lymphocytic leukemia (ALL), the most common type of childhood cancer. The FDA’s 10-member advisory panel unanimously recommended Novartis Pharmaceuticals' experimental therapy (CTL019) be approved for use in children and young adults whose leukemia doesn't respond to traditional treatments — approximately 600 patients per year in this country.
Marcela V. Maus, MD, PhD (Damon Runyon-Rachleff Innovator ’17-’18) at Massachusetts General Hospital, Boston, published results from her clinical trial with glioblastoma patients showing for the first time that CAR (chimeric antigen receptor) T cells cross the blood-brain barrier to reach tumors and appeared to be safe. These CAR T cells were targeted to EGFR variant III in glioblastoma patients. Her lab is working on next steps such as combining CAR T cells with other drugs to increase the potency of this treatment to shrink tumor size.
Fourteen years ago the Damon Runyon Cancer Research Foundation approved an application for a Damon Runyon-Lilly Clinical Investigator Award by a young researcher named Jedd Wolchok, MD, PhD of Memorial Sloan Kettering Cancer Center in New York. Jedd wanted to study an emerging field of research called immunotherapy. At the time, the field was in its infancy and had as many supporters as skeptics. But Damon Runyon’s support of Jedd proved prescient, and he became a leader in the study and application of immunotherapy to his field of melanoma research and treatment.
As a high school freshman, Peter Jauschnegg was something of a prodigy in varsity track & field.
But a day before his regional competition, the Maryland native suffered a seizure in his home that led to a diagnosis of Ewing’s sarcoma, a rare form of bone cancer. He had a tumor on the base of his skull, involving critical blood vessels and exerting pressure on his brain.
Catherine J.Wu, MD (Current Damon Runyon Physician-Scientist Mentor and Clinical Investigator '07-'12) of Dana-Farber Cancer Institute, Boston, has led one of the first studies that demonstrates the potential of personalized cancer vaccines. The study focused on six people with advanced melanoma, a type of skin cancer. The participants had surgery to remove their tumors, but about half of all such patients face a recurrence of cancer.
Marcela V. Maus, MD, PhD is a Damon Runyon Innovator at Massachusetts General Hospital and a featured speaker at our 2017 Annual Breakfast in New York earlier this month. Marcela has developed a way of engineering the body’s own immune T cells, so that they are re-directed to fight deadly brain tumors like glioblastoma. She began her remarks: “I want to introduce you to my favorite cell, the T cell. This is the cell I fell in love with before I even met my husband. It has these two amazing properties. It can kill, and it also has long-term memory. It has the potential to be curative, and it remembers what it’s seen before.”
CONNECT
1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006
